Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer's Disease

被引:15
|
作者
Weamer, Elise A. [1 ]
DeMichele-Sweet, Mary Ann A. [2 ]
Cloonan, Yona K. [3 ]
Lopez, Oscar L. [1 ,2 ]
Sweet, Robert A. [1 ,2 ,4 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA
[4] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA
基金
美国国家卫生研究院;
关键词
RANDOMIZED CONTROLLED-TRIAL; LAST; 2; DECADES; NEUROPSYCHIATRIC SYMPTOMS; NATIONAL INSTITUTE; RISK-FACTORS; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; FOLLOW-UP; DEMENTIA; HALLUCINATIONS;
D O I
10.4088/JCP.15m10617
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: To estimate the incidence of psychotic symptoms in Alzheimer's disease. Methods: The study consists of 776 elderly subjects presenting to the Alzheimer Disease Research Center at the University of Pittsburgh (Pittsburgh, Pennsylvania) between May 9, 2000, and August 19, 2014. All participants were diagnosed with mild cognitive impairment (National Institute on Aging-Alzheimer's Association workgroup criteria) or possible or probable Alzheimer's disease (National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria) and were without psychosis at entry. Psychotic symptoms were evaluated using the Consortium to Establish a Registry for Alzheimer's Disease Behavioral Rating Scale every 6 months. One-, 3- and 5-year cumulative incidences of psychosis were calculated. Results: The 1-year psychosis incidence was 10% (95% CI, 8%-12%), and this annual rate remained remarkably consistent at 3 and 5 years. Psychosis incidence was related to cognitive status at all time points. However, the incidence rate reached a plateau during the disease course. Cumulative psychosis incidence at 5 years was 61% (95% CI, 52%-69%) in individuals with moderate to severe Alzheimer's disease, not statistically significantly different from the cumulative incidence at 3 years in this group, which was 48% (95% CI, 40%-55%) or from the 5-year incidence in individuals who entered the study with mild Alzheimer's disease, which was 48% (95% CI, 41%-56%). Conclusions: Psychosis in Alzheimer's disease has been associated with a number of adverse clinical outcomes. We provide estimates of the risk of psychosis onset within clinically defined subgroups of individuals, a tool clinicians can use in treatment planning. Anticipating which subjects are at high risk for psychosis and the poor outcomes associated with it can help with family education and support decisions to implement nonpharmacologic strategies that may reduce or prevent symptoms. (C) Copyright 2016 Physicians Postgraduate Press, Inc.
引用
收藏
页码:E1564 / +
页数:10
相关论文
共 50 条
  • [31] Analysis of Naming Errors in Healthy Aging, Mild Cognitive Impairment,and Alzheimer's Disease
    Gallant, Melanie
    Lavoie, Monica
    Hudon, Carol
    Monetta, Laura
    CANADIAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY AND AUDIOLOGY, 2019, 43 (02): : 95 - 108
  • [32] Utility of the pareidolia test in mild cognitive impairment with Lewy bodies and Alzheimer's disease
    Hamilton, Calum A.
    Matthews, Fiona E.
    Allan, Louise M.
    Barker, Sally
    Ciafone, Joanna
    Donaghy, Paul C.
    Durcan, Rory
    Firbank, Michael J.
    Lawley, Sarah
    O'Brien, John T.
    Roberts, Gemma
    Taylor, John-Paul
    Thomas, Alan J.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2021, 36 (09) : 1407 - 1414
  • [33] Oral Health Status in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Data from the Zabut Aging Project
    Panzarella, Vera
    Mauceri, Rodolfo
    Baschi, Roberta
    Maniscalco, Laura
    Campisi, Giuseppina
    Monastero, Roberto
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 87 (01) : 173 - 183
  • [34] Evidence of Vestibular and Balance Dysfunction in Patients With Mild Cognitive Impairment and Alzheimer's Disease
    Bosmans, Joyce
    Gommeren, Hanne
    Gilles, Annick
    Mertens, Griet
    Van Ombergen, Angelique
    Cras, Patrick
    Engelborghs, Sebastiaan
    Vereeck, Luc
    Lammers, Marc J. W.
    Van Rompaey, Vincent
    EAR AND HEARING, 2024, 45 (01) : 53 - 61
  • [35] Perceptual and response interference in Alzheimer's disease and mild cognitive impairment
    Wang, Pan
    Zhang, Xin
    Liu, Yong
    Liu, Sainan
    Zhou, Bo
    Zhang, Zengqiang
    Yao, Hongxiang
    Zhang, Xi
    Jiang, Tianzi
    CLINICAL NEUROPHYSIOLOGY, 2013, 124 (12) : 2389 - 2396
  • [36] Dynamic balance deficit and the neural network in Alzheimer's disease and mild cognitive impairment
    Ide, Ryotaro
    Ota, Miho
    Hada, Yasushi
    Watanabe, Serina
    Takahashi, Takumi
    Tamura, Masashi
    Nemoto, Kiyotaka
    Arai, Tetsuaki
    GAIT & POSTURE, 2022, 93 : 252 - 258
  • [37] Olfactory function in mild cognitive impairment and Alzheimer's disease: A meta-analysis
    Jung, Hahn Jin
    Shin, In-Soo
    Lee, Ji-Eun
    LARYNGOSCOPE, 2019, 129 (02) : 362 - 369
  • [38] Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease
    Mecocci, Patrizia
    Polidori, Maria Cristina
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2012, 1822 (05): : 631 - 638
  • [39] Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment
    Liu, Weilin
    Lin, Huawei
    He, Xiaojun
    Chen, Lewen
    Dai, Yaling
    Jia, Weiwei
    Xue, Xiehua
    Tao, Jing
    Chen, Lidian
    TRANSLATIONAL PSYCHIATRY, 2020, 10 (01)
  • [40] Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment
    Visser, Pieter Jelle
    Wolf, Henrike
    Frisoni, Giovanni
    Gertz, Hermann-Josef
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 365 - 368